期刊文献+

雷帕霉素对甲氨蝶呤诱导急性淋巴细胞白血病EU-4细胞凋亡的影响 被引量:3

Influence of Rapamycin on apoptosis of acute lymphoblastic leukemia EU -4 cells induced by Methotrexate
原文传递
导出
摘要 目的探讨雷帕霉素(RAPA)对甲氨蝶呤(MTX)诱导急性淋巴细胞白血病(ALL)EU-4细胞凋亡的影响。方法分别使用5μg/L、10μg/L、25μg/L、50μg/L和100μg/L的RAPA预处理EU-4细胞0.5h,RAPA未处理组作为对照组,收集细胞,Westernblot检测LC-3蛋白,流式细胞技术检测凋亡率。观察不同质量浓度的RAPA预处理对Eu-4细胞自噬和凋亡的影响,确定RAPA预处理浓度。将Eu-4细胞分为RAPA预处理组和未处理组,分别使用0.05μmol/L、0.10/μmol/L和0.20μmol/L的MTX作用24h,流式细胞技术检测凋亡率,Westernblot检测LC-3蛋白,酶标仪测定吸光度(A_562),根据标准曲线计算样品的蛋白浓度。结果检测对照组和不同浓度RAPA预处理组的EU-4细胞凋亡率显示,对照组,5μg/L、10μg/L、25μg/L、50μg/L和100μg/LRAPA预处理组Eu-4细胞的凋亡率分别为(7.51±0.32)%、(7.33±0.41)%、(7.71±0.51)%、(7.63±0.38)%、(7.80±0.43)%和(16.66±0.87)%,5μg/L、10μg/L、25μg/L和50μg/LRAPA预处理组EU-4细胞的凋亡率与对照组比较差异均无统计学意义(t=0.427、-0.417、-0.297、-3.561,均P〉0.05),而100μ/gL RAPA预处理组Eu-4细胞的凋亡率显著高于对照组,差异有统计学意义(t=-28.815,P〈0.01)。根据Westernblot和流式细胞技术的检测结果综合考虑,选取50μg/L作为RAPA预处理的浓度。流式细胞技术检测RAPA预处理组和未处理组MTX作用24h后EU-4细胞的凋亡率显示,RAPA预处理组用0.05μmol/L、0.10μmol/L和0.20μmol/LMTX作用24h后,EU-4细胞的凋亡率分别为(50.23±2.11)%、(66.88±2.89)%和(73.11±2.67)%,未处理组0.05μmol/L、0.10μmol/L和0.20μmol/L MTX作用24h后,EU-4细胞的凋亡率分别为(22.53±1.67)%、(42.82±2.26)%和(53.22±1.93)%。相同浓度的MTX作用24h后,RAPA预处理组Eu-4细胞的凋亡率均显著高于未处理组,差异均有统计学意义(t=12.693、66.148、14.429,均P〈0.01)。结论RAPA预处理后,较低剂量的MTX即可诱导急性淋巴细胞白血病Eu-4细胞大量凋亡。 Objective To explore the influence of Rapamycin (RAPA) on apoptosis of acute lymphoblastic leukemia EU - 4 cells induced by Methotrexate (MTX). Methods EU - 4 cells were pretreated O. 5 h with 5 μg/L, 10 μg/L,25μg/L,50 μg/L and 100 μg/L RAPA. RAPA untreated group was set up as control group. The cells were col- lected and the expression of LC - 3 was assayed by using Western blot. The apoptosis of EU - 4 cells was detected by using flow cytometry(FCM). The effects of different concentrations of RAPA pretreatment on autophagy and apoptosis of EU - 4 cells were observed, and the pretreatment concentration of RAPA was determined. EU - 4 ceils were divided into RAPA pretreatment group and untreated group. The ceils were treated with 0.05 μmol/L,0. 10 μmol/L and 0.20 μmol/L MTX for 24 h, respectively. The apoptotic rate was detected by using FCM. Western blot was performed to test the expression of LC -3 protein,while the absorbance(A_562 ) was measured by using microplate reader,and the protein concentration in the sample was calculated according to the standard curve. Results The apoptotic rates of EU -4 cells in the control group and the different concentrations of RAPA pretreatment group showed that the control group, 5 μg/L, 10 μg/L,25 μg/L, 50 μg/L and 100 μg/L RAPA were ( 7.51 ± 0.32 ) %, (7.33 ± 0.41 ) %, ( 7.71 ± 0. 51 ) % , (7. 63 ± 0.38 ) %, ( 7.80 ± 0.43 ) % and ( 16.66 ± 0.87 ) % , respectively. The apoptotic rates of EU - 4 cells in the 5 μg,/L, 10 μg/L,25 μg/L and 50 μg/L RAPA pretreatment group had no significant difference from those in the control group( t = 0.427, - 0. 417, - 0. 297, - 3. 561, all P 〉 0.05 ). The apoptotie rate of EU - 4 cells in 100 μg/L RAPA pretreatment group was significantly higher than that in control group, and the difference was significant (t = - 28. 815 ,P 〈0. 01 ). Combined with the results of Western blot and FCM ,50 μg/L was used as the pretreatment of RAPA. The apoptosis rates of EU - 4 cells in RAPA pretreatment group were (50.23 ± 2.11 ) %, (66.88 ± 2.89) % and (73.11 ± 2.67) % after treated with 0.05 μmol/L,0.10 μmol/L and 0.20 μmol/L MTX for 24 h, respectively. The apoptotic rates of EU - 4 cells in RAPA unpretreatment group were (22.53 ± 1.67) %, (42.82 ± 2.26) % and (53.22 ± 1.93)% after treated with 0.05 μmol/L,0. 10 μmol/L and 0.20 μmol/L MTX for 24 h, respectively. The apoptotic rates of EU -4 cells in RAPA pretreatment group were significantly higher than those in untreated group in the same concentration of MTX treatment after 24 h, and the differences were significant ( t = 12. 693,66. 148,14. 429 ; all P 〈0. 01 ). Conclusion With RAPA pretreatment,relative low dose MTX can induce a great deal of acute lympho- blastic leukemia EU -4 cells apoptosis.
出处 《中华实用儿科临床杂志》 CSCD 北大核心 2017年第14期1101-1103,共3页 Chinese Journal of Applied Clinical Pediatrics
关键词 急性淋巴细胞白血病 雷帕霉素 甲氨蝶呤 Acute lymphoblastic leukemia Rapamycin Methotrexate
  • 相关文献

参考文献3

二级参考文献32

  • 1顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:472
  • 2Freifeid AG, Bow EJ, Sepkowitz KA, et al. Clinical prac- tice guideline foe the use of antimicrobial agents in neu- tropents patients with cancer:2010 update by the Infec- tions Diseases Society of America[J].Clin Infect Dis,2011,52(4):427-431.
  • 3Suthandiram S, Gan GG, Zain SM, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies [ J ]. Pharmacogenomics ,2014,15 ( 11 ) : 1479 - 1494.
  • 4Wang SM, Sun LL, Zeng WX, et al. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia [ J ]. Cancer Chemother Pharmacol,2014,74 ( 2 ) :283 - 289.
  • 5Csordas K, Lautner-Csorba O, Semsei AF, et al. Associations of novel ge- netic variations in the folate-related and ARID5B genes with the phar- macokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia [ J ]. Br J Haemato1,2014,166 ( 3 ) :410 - 420.
  • 6Goriar K,Kova V,Jazbec J,et al. Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteo- sarcoma [ J ]. Pharmacogenet Genomics, 2014,24 ( 10 ) : 514 - 521.
  • 7Radtke S, Zolk O, Renner B, et al. Germline genetic variations in metho- trexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia [ J ]. Blood, 2013,121 (26) :5145 -5153.
  • 8Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmaeokinetics and clinical effects [ J ]. J Clin Oncol, 2009,27 ( 35 ) : 5972 - 5978.
  • 9Rarnsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotre- xate clearance replicates SLCO1 B1 [ J ]. Blood, 2013,121 ( 6 ) : 898 - 904.
  • 10Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverseevents of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0 [ J ]. J Am Aead Dermatol, 2012,67 ( 5 ) : 1025 - 1039.

共引文献11

同被引文献17

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部